SCHEMBL2953188

SCHEMBL2953188

CC(C)C(=O)OCOC(=O)NC(O)CCP(=O)(O)CC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
METAP2 P50579 1/20 0.33
METAP1 P53582 1/20 0.32
MMP2 P08253 4/20 0.32
CA12 O43570 3/20 0.32
CA1 P00915 3/20 0.32
CA2 P00918 3/20 0.32
CA9 Q16790 3/20 0.32
CTSK P43235 3/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
MMP8 P22894 2/20 0.30
MMP1 P03956 1/20 0.30
MMP3 P08254 1/20 0.30
MMP9 P14780 1/20 0.30
REN P00797 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956637 0.88 METAP1 (0.32) CYP1A2CYP3A4METAP2METAP1MMP2
SCHEMBL2948784 0.87 METAP2 (0.32) CYP1A2CYP3A4METAP2METAP1CTSK
SCHEMBL2949220 0.87 METAP1 (0.33) CYP1A2CYP3A4METAP2METAP1
SCHEMBL2946312 0.86 ADRB2 (0.33) METAP1MMP2CA12CA1CA2
SCHEMBL2952958 0.85 CTSK (0.34) CYP1A2CYP3A4METAP2METAP1MMP2
SCHEMBL2957743 0.81 MMP8 (0.33) CYP1A2CYP3A4MMP2CA12CA1
SCHEMBL2946514 0.78 MMP8 (0.33) CYP1A2CYP3A4METAP1MMP2CA12
SCHEMBL2952272 0.78 CTSK (0.34) CYP1A2CYP3A4METAP1MMP2CA12
SCHEMBL2949114 0.77 GABBR2 (0.36)
SCHEMBL2948636 0.77 CTSK (0.33) CYP1A2CYP3A4METAP2METAP1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585996-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2009-09-08 US claimed
US-7749985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2010-07-06 US disclosed
US-20090286759-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2009-11-19 US disclosed
US-7585996-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2009-09-08 US disclosed
US-20080146526-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286759-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE APEH, NAPEPLD, AASDHPPT CYP1A2 1321/4885CYP3A4 540/4885METAP2 1289/4885
US-20080146526-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use APEH, NAPEPLD, AASDHPPT CYP1A2 1321/4885CYP3A4 540/4885METAP2 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.